TY - JOUR T1 - Each patient is a research biorepository: Informatics-enabled research on surplus clinical specimens via the Living BioBank JF - medRxiv DO - 10.1101/2020.09.25.20199679 SP - 2020.09.25.20199679 AU - Alexander V. Alekseyenko AU - Bashir Hamidi AU - Trevor D. Faith AU - Keith A. Crandall AU - Jennifer G. Powers AU - Christopher L. Metts AU - James E. Madory AU - Steven L. Carroll AU - Jihad S. Obeid AU - Leslie A. Lenert Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/27/2020.09.25.20199679.abstract N2 - The ability to analyze human specimens is the pillar of modern-day translational research. To enhance the research availability of relevant clinical specimens, we developed the Living BioBank (LBB) solution, which allows for just-in-time capture and delivery of phenotyped surplus laboratory medicine specimens. The LBB is a system-of-systems integrating research feasibility databases in i2b2, a real time clinical data warehouse, and an informatics system for institutional research services management (SPARC). LBB delivers de-identified clinical data and laboratory specimens. We further present an extension to our solution, the Living µBiome Bank, that allows the user to request and receive phenotyped specimen microbiome data. We discuss the details of the implementation of the LBB system and the necessary regulatory oversight for this solution. The conducted institutional focus group of translational investigators indicates an overall positive sentiment towards potential scientific results generated with the use of LBB. Reference implementation of LBB is available at https://LivingBioBank.musc.edu.Competing Interest StatementAVA is a scientific advisory board member for Second Genome, Inc., which has not contributed to this research.Funding StatementAVA, BH, LAL, JSO, KC, and JGP are supported by NIH/NCATS R21 TR002513. AVA and BH are supported by NIH/NLM R01 LM012517. SLC is supported by NIH/NCI 5P30CA138313, 1UM1CA239752 and 1U54CA210962 and by NIH/NIA 1RO1AG055132. The project described was supported by the NIH/NCATS UL1 TR001450.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The development of LBB proceeded under regulatory consultation with the MUSC Institutional Review Board (IRB). LBB was determined to be a process and thus exempt from review. From the MUSC IRB standpoint the phenotyped specimens do not constitute human subjects derived materials and therefore are exempt from regulations regarding informed consent. Further the phenotypes used for specimen capture are deemed generic enough to not constitute identifiable data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials. ER -